Lucentis(ranibizumab)
Byooviz, Cimerli, Lucentis, Ranivisio, Susvimo, Ximluci (ranibizumab) is an antibody pharmaceutical. Ranibizumab was first approved as Lucentis on 2006-06-30. It is used to treat diabetic retinopathy, macular edema, and retinal vein occlusion in the USA. It has been approved in Europe to treat choroidal neovascularization, degenerative myopia, diabetes complications, diabetic retinopathy, and macular edema amongst others. The pharmaceutical is active against vascular endothelial growth factor A, long form. In addition, it is known to target Vascular permeability factor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Byooviz, Cimerli, Lucentis, Susvimo
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| macular edema | — | D008269 | — |
| retinal vein occlusion | EFO_1001157 | D012170 | H34.81 |
| diabetic retinopathy | EFO_0003770 | D003930 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
ranibizumab, Cimerli, Coherus BioSciences, Inc. | |||
| 10/3/2023 | Interchangeable excl. | ||
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| J2778 | Injection, ranibizumab, 0.1 mg |
Clinical
Clinical Trials
628 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | 12 | 17 | 12 | 4 | 5 | 40 |
| Macular edema | D008269 | — | — | 13 | 17 | 9 | 2 | 3 | 36 |
| Edema | D004487 | — | R60.9 | 11 | 16 | 7 | 2 | 2 | 30 |
| Retinal vein occlusion | D012170 | EFO_1001157 | H34.81 | 8 | 4 | 4 | 2 | 1 | 16 |
| Pathologic neovascularization | D009389 | — | — | 9 | 5 | 3 | 1 | 3 | 16 |
| Choroidal neovascularization | D020256 | — | — | 7 | 3 | 2 | 1 | 2 | 12 |
| Wet macular degeneration | D057135 | EFO_0004683 | — | — | 4 | 3 | 2 | — | 8 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Retinal diseases | D012164 | — | H35.9 | 4 | 4 | 4 | — | 1 | 13 |
| Diabetic retinopathy | D003930 | EFO_0003770 | — | 2 | 4 | 4 | — | — | 9 |
| Glaucoma | D005901 | EFO_0000516 | H40 | 2 | 3 | 1 | — | 1 | 4 |
| Dissociative disorders | D004213 | — | F44.1 | — | 3 | 1 | — | — | 3 |
| Retinal detachment | D012163 | EFO_0005773 | H33.2 | — | 2 | 1 | — | — | 2 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | 2 | — | — | 2 |
| Scotoma | D012607 | — | H53.12 | — | — | 1 | — | — | 1 |
| Diffuse cerebral sclerosis of schilder | D002549 | Orphanet_726 | G31.81 | — | 1 | 1 | — | — | 1 |
| Retinal vasculitis | D031300 | EFO_1001156 | H35.06 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Polypoidal choroidal vasculopathy | D000092342 | — | — | 6 | 5 | — | — | — | 6 |
| Vascular diseases | D014652 | EFO_0004264 | I77 | 5 | 4 | — | — | — | 5 |
| Telangiectasis | D013684 | — | — | 3 | 2 | — | — | — | 4 |
| Radiation injuries | D011832 | — | T66 | 2 | 1 | — | — | — | 3 |
| Uveitis | D014605 | EFO_1001231 | H20.9 | 2 | 2 | — | — | — | 3 |
| Melanoma | D008545 | — | — | 2 | 1 | — | — | — | 3 |
| Ischemia | D007511 | EFO_0000556 | — | 3 | 1 | — | — | — | 3 |
| Inflammation | D007249 | MP_0001845 | — | 1 | 2 | — | — | — | 2 |
| Histoplasmosis | D006660 | EFO_0007310 | B39 | 1 | 2 | — | — | — | 2 |
| Retinal degeneration | D012162 | — | — | — | 1 | — | — | — | 1 |
Show 13 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | D010146 | EFO_0003843 | R52 | 1 | — | — | — | — | 1 |
| Hereditary hemorrhagic telangiectasia | D013683 | — | I78.0 | 1 | — | — | — | — | 1 |
| Epistaxis | D004844 | EFO_0003895 | R04.0 | 1 | — | — | — | — | 1 |
| Eye diseases | D005128 | EFO_0003966 | H44 | 1 | — | — | — | — | 1 |
| Pathologic processes | D010335 | — | — | 1 | — | — | — | — | 1 |
| Pterygium | D011625 | — | H11.0 | 1 | — | — | — | — | 1 |
| Cataract | D002386 | EFO_0001059 | H26.9 | 1 | — | — | — | — | 1 |
| Depression | D003863 | — | F33.9 | 1 | — | — | — | — | 1 |
| Corneal neovascularization | D016510 | EFO_1000880 | H16.4 | 1 | — | — | — | — | 1 |
| Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | 1 | — | — | — | — | 1 |
Show 6 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | — | — | 1 | 1 |
| Retinal neovascularization | D015861 | — | H35.05 | — | — | — | — | 1 | 1 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Ranibizumab |
| INN | ranibizumab |
| Description | Immunoglobulin G1, anti-(human vascular endothelial growth factor) Fab fragment (human-mouse monoclonal rhuFAB V2 gamma1-chain), disulfide with human-mouse monoclonal rhuFAB V2 kappa-chain |
| Classification | Antibody |
| Drug class | monoclonal antibodies |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | >1CZ8:H,Y|HEAVY CHAIN OF NEUTRALIZING ANTIBODY
EVQLVESGGGLVQPGGSLRLSCAASGYDFTHYGMNWVRQAPGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAY
LQMNSLRAEDTAVYYCAKYPYYYGTSHWYFDVWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPV
TVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHL
>1CZ8:L,X|LIGHT CHAIN OF NEUTRALIZING ANTIBODY
DIQLTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKPGKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISSLQP
EDFATYYCQQYSTVPWTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQ
ESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Identifiers
| PDB | 1CZ8 |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201825 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB01270 |
| UNII ID | ZL1R02VT79 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
VEGFA
VEGFA
Organism
Homo sapiens
Gene name
VEGFA
Gene synonyms
NCBI Gene ID
—
Protein name
Vascular endothelial growth factor A
Protein synonyms
Vascular permeability factor
Uniprot ID
Mouse ortholog
—
—
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Byooviz – Biogen
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Cimerli – Coherus BioSciences
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Lucentis – Novartis
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Lucentis – Roche
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 13,919 documents
View more details
Safety
Black-box Warning
Black-box warning for: Susvimo
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
29,511 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use